Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience

详细信息    查看全文

• 作者：Diana Bell ; Ehab Y. Hanna ; Abbas Agaimy ; Annikka Weissferdt
• 关键词：Sinonasal carcinoma ; Basaloid ; Rhabdoid ; SMARCB1 (INI1) ; Targeted therapy
• 刊名：Virchows Archiv
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：467
• 期：6
• 页码：649-656
• 全文大小：3,366 KB
• 参考文献：1.Bell D, Hanna EY (2013) Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther 13:285-6CrossRef PubMed
  2.Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, Knoll A, Iro H, Haller F, Hartmann A (2014) SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol 38:1274-1PubMedCentral CrossRef PubMed
  3.Bishop JA, Antonescu CR, Westra WH (2014) SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 38:1282-PubMedCentral CrossRef PubMed
  4.Strehl JD, Wachter DL, Fiedler J, Heimerl E, Beckmann MW, Hartmann A, Agaimy A (2015) Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. Ann Diagn Pathol 19:198-02CrossRef PubMed
  5.Agaimy A (2014) The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 21:394-10CrossRef PubMed
  6.Kim KH, Roberts CW (2014) Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 207:365-2PubMedCentral CrossRef PubMed
  7.Roberts CW, Biegel JA (2009) The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 8:412-PubMedCentral CrossRef PubMed
  8.Agaimy A, Geddert H, M?rkl B, et al. SMARCB1(INI1)-deficient sinonasal carcinomas: expanding the morphological spectrum of a recently described entity. Lab Invest 95:318A-318A
  
• 作者单位：Diana Bell (1) (2)
  Ehab Y. Hanna (2)
  Abbas Agaimy (3)
  Annikka Weissferdt (1)
  
  1. Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA
  2. Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA
  3. Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pathology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2307

文摘

Sinonasal carcinomas are rare and of diverse histology, often involve critical anatomic structures, and are associated with an aggressive clinical course and poor prognosis. Differentiating these tumor types may have clinical impact as advances in entity-specific therapeutic intervention could increase survival and quality of life and occasionally result in a cure. Recently, a unique subset of sinonasal carcinomas characterized by basaloid/rhabdoid tumor morphology and loss of expression of SMARCB1 (INI1) was identified. We tested a total of 256 tumors including head and neck (n--41) and thoracic (n--5) tumors with basaloid/rhabdoid morphology for loss of expression of SMARCB1 (INI1) using full tissue sections and tissue microarrays. Among these, four tumors of the sinonasal tract were found to be SMARCB1 (INI1) deficient and were reclassified as SMARCB1 (INI1)-deficient sinonasal carcinomas. These tumors appear to be restricted to the sinonasal tract, and their unique clinical, morphological, and immunohistochemical features seem to warrant inclusion as a separate new entity among the existing high-grade sinonasal neoplasms. Separation from the other types of sinonasal malignancies is important as the identification of SMARCB1 (INI1) deficiency may provide a new target for novel treatment approaches and may ultimately lead to improved patient survival. Keywords Sinonasal carcinoma Basaloid Rhabdoid SMARCB1 (INI1) Targeted therapy